drugset / Trial / NCT00346866

Anecortave Acetate Versus Placebo in AMD Patients Following PDT

NCT00346866

Phase 2 Completed 136 enrolled Alcon Research
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study was to evaluate the efficacy of anecortave acetate for depot suspension (30 mg and 15 mg) plus PDT versus PDT alone with respect to maintenance of visual acuity in patients with wet AMD.

Timeline

Start
2000-05
Primary completion
2001-12
Completion
2001-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Anecortave Acetate Small molecule 15 mg
Subject Anecortave Acetate Small molecule 30 mg

Indications

No indication recorded.